Comparison
Semaglutid vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
910463-68-2
868844-74-0
Molecular weight
4113.6 g/mol
1075.16 g/mol
Half-life
165 h
no data
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
3
of which in humans
3
1
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
5
1